NXL Fair Value Estimate
$0.0879.4% overvalued
Blended fair value estimate based on DCF, Graham Number, and earnings-based models.
Nexalin Technology Inc
Exchange: NASDAQSector: HealthcareIndustry: Medical Devices
Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin’s products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, and Oman.
Did you know?
Holds 654783.0x more cash than debt — a strong balance sheet.
Current Price
$0.38
+0.03%GoodMoat Value
$0.08
79.4% overvaluedProfile
Valuation (TTM)
Market Cap$7.10M
P/E-0.86
EV—
P/B1.89
Shares Out18.65M
P/Sales23.52
Revenue$301647.00
EV/EBITDA—
Nexalin Technology Inc (NXL) Valuation
NXL Valuation Metrics
FCF$-4.96M
FCF Growth Rate—
EPS Growth (CAGR)—
WACC10.00%
Fair Value Models
Graham Number, PEG-based, and Earnings-based models
View Fair Value →NXL Valuation & Fair Value Analysis
Nexalin Technology Inc (NXL) valuation analysis using multiple fair value methodologies. GoodMoat calculates a blended fair value target using discounted cash flow (DCF) analysis, the Graham Number, and earnings-based valuation models.
The GoodMoat Fair Value target for Nexalin Technology Inc is $0.08. The current stock price is $0.38, suggesting the stock is 386.2% overvalued.
The price-to-earnings (P/E) ratio is -0.86. Price-to-book ratio is 1.89. Price-to-sales ratio is 23.52. PEG ratio is 0.02.
GoodMoat's valuation models include the Graham Number (based on EPS and book value), an earnings-based model (discounted future EPS), and a PEG-adjusted valuation. The three models are averaged to produce a blended fair value estimate. Use these tools alongside the DCF calculator and reverse DCF to form a comprehensive view of Nexalin Technology Inc's intrinsic value.